» Articles » PMID: 31501263

Hepatitis C Virus Structure: Defined by What It Is Not

Overview
Specialty General Medicine
Date 2019 Sep 11
PMID 31501263
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) represents an important and growing public health problem, chronically infecting an estimated 70 million people worldwide. This blood-borne pathogen is generating a new wave of infections in the United States, associated with increasing intravenous drug use over the last decade. In most cases, HCV establishes a chronic infection, sometimes causing cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Although a curative therapy exists, it is extremely expensive and provides no barrier to reinfection; therefore, a vaccine is urgently needed. The virion is asymmetric and heterogeneous with the buoyancy and protein content similar to low-density lipoparticles. Core protein is unstructured, and of the two envelope glycoproteins, E1 and E2, the function of E1 remains enigmatic. E2 is responsible for specifically binding host receptors CD81 and scavenger receptor class B type I (SR-BI). This review will focus on structural progress on HCV virion, core protein, envelope glycoproteins, and specific host receptors.

Citing Articles

The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.

Yuan H, Xu R, Li S, Zheng M, Tong Q, Xiang M MedComm (2020). 2025; 6(3):e70121.

PMID: 40060195 PMC: 11890166. DOI: 10.1002/mco2.70121.


Exploring T-Cell Immunity to Hepatitis C Virus: Insights from Different Vaccine and Antigen Presentation Strategies.

Costa G, Sautto G Vaccines (Basel). 2024; 12(8).

PMID: 39204016 PMC: 11359689. DOI: 10.3390/vaccines12080890.


Understanding the relationship between HCV infection and progression of kidney disease.

Zhang M, Han Z, Lin Y, Jin Z, Zhou S, Wang S Front Microbiol. 2024; 15:1418301.

PMID: 39006752 PMC: 11239345. DOI: 10.3389/fmicb.2024.1418301.


Antiviral Protein-Protein Interaction Inhibitors.

Markovic V, Szczepanska A, Berlicki L J Med Chem. 2024; 67(5):3205-3231.

PMID: 38394369 PMC: 10945500. DOI: 10.1021/acs.jmedchem.3c01543.


Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies.

Metcalf M, Janus B, Yin R, Wang R, Guest J, Pozharski E Nat Commun. 2023; 14(1):3980.

PMID: 37407593 PMC: 10322937. DOI: 10.1038/s41467-023-39659-z.


References
1.
Zhou D, Zhao Y, Kotecha A, Fry E, Kelly J, Wang X . Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat Microbiol. 2018; 4(3):414-419. DOI: 10.1038/s41564-018-0319-z. View

2.
Dreux M, Dao Thi V, Fresquet J, Guerin M, Julia Z, Verney G . Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 2009; 5(2):e1000310. PMC: 2636890. DOI: 10.1371/journal.ppat.1000310. View

3.
Lindenbach B, Evans M, Syder A, Wolk B, Tellinghuisen T, Liu C . Complete replication of hepatitis C virus in cell culture. Science. 2005; 309(5734):623-6. DOI: 10.1126/science.1114016. View

4.
Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R . Binding of hepatitis C virus to CD81. Science. 1998; 282(5390):938-41. DOI: 10.1126/science.282.5390.938. View

5.
Kato T, Miyamoto M, Furusaka A, Date T, Yasui K, Kato J . Processing of hepatitis C virus core protein is regulated by its C-terminal sequence. J Med Virol. 2003; 69(3):357-66. DOI: 10.1002/jmv.10297. View